key: cord-0751085-i3id4rm0 authors: Patel, Sankalp P.; Solomon, Brian J.; Pascotto, Robert D.; D'Orazio, Stephen E.; Navas, Elsy V.; Cubeddu, Robert J.; Cudemus, Gaston A. title: Uninterrupted Continuation of VV-ECMO without Anticoagulation for 44 days in COVID-19 ARDS: A Precarious Quandary date: 2022-04-10 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2022.04.006 sha: a856553507c3fd2749edd2e7338af697b150b731 doc_id: 751085 cord_uid: i3id4rm0 Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population who do not respond to conventional medical therapy suffering from severe COVID-19 acute respiratory distress syndrome (ARDS). This therapy necessitates the utilization of anticoagulation, whether unfractionated heparin or bivalirudin, to prevent thrombotic complications. Scarce are reports of VV-ECMO implementation leading to acute hemorrhage mandating cessation of anticoagulation in a patient suffering from COVID-19 ARDS. Herein, we report a case of a successful outcome in a COVID-19 ARDS patient who suffered an acute hemorrhagic complication leading to pre-emptive termination of systemic anticoagulation. We believe this to be one of the first such cases in the literature. termination of systemic anticoagulation. We believe this to be one of the first such cases in the literature. Keywords: Extracorporeal Membrane Oxygenation, COVID-19, acute respiratory distress syndrome, thrombotic complications, hemorrhage, anticoagulation, survival Heavily re-instituted during the H1N1 flu epidemic, veno-venous extracorporeal membrane oxygenation has remained a revolutionary treatment option for adult patients with severe acute respiratory distress syndrome providing pulmonary support as either a bridge to lung transplantation or a path to recovery. When severe acute respiratory distress syndrome (ARDS) from COVID-19 can no longer be managed with mechanical ventilatory support alone, a collaborative decision is made to determine candidacy for VV-ECMO support. As intensivists become tasked with managing large volumes of critically ill patients, the advent of systematic protocolized approaches at many institutions has led to efficacious initiation, maintenance, and weaning of VV-ECMO. The majority of ECMO protocols involve systemic anticoagulation with very adherent monitoring of activated clotting time (ACT), anti-Xa, or activated partial thromboplastin time (aPTT) to ensure minimizing thromboembolic complications 1 . Nonetheless, systemic anticoagulation also comes with a complication rate which cannot be ignored. Hemorrhagic complications from ECMO can be life-threatening if left unnoticed 2 . Timely recognition of hemorrhage along with prompt cessation of anticoagulants is crucial; nonetheless, locating the source for hemorrhage is also paramount. Upon identification of hemorrhage, there is no setpoint in time for how long one should hold off on anticoagulation. Bleeding severity, location, and overall clinical status of each individualized patient all play a key role in guiding the decision of an ECMO team to withhold or cautiously continue with anticoagulation. This decision can be overwhelming for a physician alone, thus input from a multi-disciplinary ECMO team is necessary. We highlight a patient who encountered an intra-abdominal hemorrhage likely secondary to systemic anticoagulation in conjunction with VV-ECMO initiated due to COVID-19 ARDS. This report serves to illustrate the complexity in proceeding with VV-ECMO management in a patient suffering from severe COVID-19 ARDS with minimal use of systemic anticoagulation. A 43-year-old man with no significant medical history, unvaccinated against SARS-CoV-2, presented to our institution reporting an 8-day history of cough, myalgias, sore throat, and dyspnea (height: 165cm; weight: 106 kg; BMI: 33.8 kg/m 2 ). On arrival to our hospital, viral PCR confirmed positivity for SARS-CoV-2 infection, and the patient was noted to be tachypneic with a respiratory rate varying from 25-40 breaths per minute and hypoxic with initial oxygen saturation (SpO2) of 82% on room air improving to 95% with placement of non-rebreather mask. An arterial blood gas (ABG) was obtained unveiling a pH of 7.40, PaCO2 of 37.8 mmHg, and PaO2 of 56.3 mmHg with a PaO2:FiO2 ratio of 128 indicating moderate ARDS and he was admitted to the intensive care unit. His oxygenation was supported with non-invasive positive pressure ventilation (NIPPV), but after persistent tachypnea and labored breathing, the patient agreed to mechanical ventilatory support and was intubated. Throughout his initial course, the patient underwent fine ventilatory adjustments to target optimal settings in accordance with his lung mechanics to no avail. Serial ABG's continued to reveal worsening of hypoxic respiratory failure in conjunction with hypercapnic respiratory failure as well, with ABG 4 days after placement on ventilatory support revealing pH of 7.40, PaCO2 of 79 mmHg, PaO2 of 72 mmHg, and a PaO2:FiO2 ratio of 79. At this time, a multidisciplinary team collaborated and decided to implement VV-ECMO as means to further support the patient's worsening respiratory failure. The patient was transferred to our neighboring campus, wherein the ECMO team was consulted. He was brought directly our ECMO intensive care unit and cardiothoracic surgery was notified of his arrival. ECMO cannulation proceeded in the ICU, and the patient was appropriately prepped and sterilely draped. Access was obtained in the right internal jugular vein with serial dilation under fluoroscopic guidance up to a 22Fr return cannula inserted in the jugular venous tract, with the tip terminating near the junction of the superior vena cava (SVC) and the right atrium (RA). Subsequent access was obtained in the right femoral vein, with dilation up to a 25Fr drainage cannula, confirmed just below the level of the diaphragm with fluoroscopy. The ECMO circuit was initiated thereafter without complications, and the patient's SpO2 rose to > 90% immediately. The sweep was gradually titrated to 6L/min, pump speed of 3500 rotations per minute (RPM) generating a flow of 4.5L/min, and the patient remained under concomitant mechanical ventilatory support. He was also placed on a bivalirudin infusion to maintain oxygenation circuit permeability and prevent thrombosis as part of our VV-ECMO anticoagulation protocol. The following day after ECMO cannulation, the patient's hemoglobin dropped from 12.9 to 9.7 g/dL and a non-contrast CT Chest Abdomen and Pelvis was performed ( Figure 1 ). As (Figure 2) , the patient was brought down to interventional radiology suite and underwent mesenteric angiography. This revealed a pseudoaneurysm from the left anterior branch of the superior rectal artery believed to be the source of spontaneous hemorrhage, for which coil embolization was performed without complication. Our patient's hemoglobin subsequently remained stable and continuous weaning of sweep ensued. The day after coil embolization, our patient's oxygenator began clotting, and sweep was weaned over 48 hour period gradually from 4Lmin to 2Lmin to 0L/min, where it remained 24 hours thereafter. Decision was made to pursue decannulation after 59 days on VV-ECMO support (44 of which were without systemic anticoagulation), as our patient's native lung mechanics appeared to be improving based on ABG's and observed compliance. He underwent removal of the Crescent TM cannula at the bedside without complication after ECMO circuit was no longer circulating and was continued on mechanical ventilatory support alone. He was able to wean off the ventilator and transfer to the medical floor, where he was eventually discharged home on 2L nasal cannula and doing very well. There have been numerous reports in the literature regarding the implementation of veno- Herein, we showcased the first presumed case in the literature of a COVID-19 ARDS patient necessitating VV-ECMO with minimal use of systemic anticoagulation being successfully weaned off and decannulated without major complications. This report serves to showcase the challenging dilemma posed by withholding anticoagulation in the setting of a prothrombotic viral infection in conjunction with VV-ECMO. Anticoagulation Monitoring Under ECMO Support: A Comparative Study Between the Activated Coagulation Time and the Anti-Xa Activity Assay Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation Prolonged venovenous extracorporeal membrane oxygenation without anti-coagulation: a case of Goodpasture syndrome-related pulmonary haemorrhage Non-heparinized ECMO serves a rescue method in a multitrauma patient combining pulmonary contusion and nonoperative internal bleeding: a case report and literature review Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. Ann Cardiothorac Surg Feasibility of Venovenous Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation Thrombosis in COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Figure 2